ARCHIVES

As patients worry about COX-2 inhibitors, scientists and FDA review toxicity data.

This article is from The Cancer Letter archive.

Vol. 30 No. 40 | October 22, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: WHI Revises Protocol After Study Finds High Rate Of Endometrial Hyperplasia

January 27, 1995

In Brief: NIH Funding For Shannon Awards To Fall, Eight Institutes Decide Not To Participate

August 13, 1993

Gallo Actively Searching For New Position

July 1, 1994

Funding Opportunities

October 25, 2002

FDA Approves Taxotere For Node+ Breast Cancer

August 27, 2004

In Brief: Six On NCA Serve Out Terms, No Successors in Sights DCBD Renamed With ‘Centers’ In Title

February 9, 1990